V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Myriad Genetics Executive Compensation (FY25)

MYGN · Executive and director compensation, fiscal 2024 to 2025

The paid brief on Myriad Genetics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 21, 2026Latest filing (8-K): June 4, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Myriad Genetics brief$1,500Get the executive brief
290 figures on this page: 279 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Samraat Raha
Median of the other named officers
$1,895,166
7 officers, excluding the chief executive
Latest say-on-pay support
=
June 4, 2026
Chief executive pay ratio
◇
To the median employee

More on Myriad Genetics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Samraat Raha: $4,389,327 → $5,686,740 (29.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Myriad Genetics' chief executive and what were they paid?
Total compensation for Samraat Raha, President and Chief Executive Officer, came to $5,686,740 in fiscal 2025. Raha's total was 29.6% higher than the $4,389,327 reported for fiscal 2024.
What was Myriad Genetics' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 95.0% support at the meeting held June 4, 2026.
Which companies are in Myriad Genetics' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals Inc., Alkermes plc, Bio-Techne Corporation, BioMarin Pharmaceutical Inc. and Coherus BioSciences, Inc., among others.
What is Myriad Genetics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 60:1, against median employee compensation of $97,407.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Paul Diaz
President and Chief Executive Officer
◇—◇—◇—◇◇
Scott Leffler
Chief Financial Officer
◇◇◇—◇—◇◇
Samraat Raha
Chief Operating Officer
◇—◇—◇—◇◇
Mark Verratti
Chief Commercial Officer
◇—◇—◇—◇◇
Dale Muzzey
Chief Scientific Officer
◇—◇—◇—◇◇
R. Bryan Riggsbee
Former Chief Financial Officer
Departed during or after this year
◇—————◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Donnelly
Chief Commercial Officer
◇◇◇—◇—◇◇
Samraat Raha
President and Chief Executive Officer
◇—◇—◇—◇◇
Mark Verratti
Chief Operating Officer
◇—◇—◇—◇◇
Scott Leffler
Former Chief Financial Officer
Departed during or after this year
◇—◇———◇◇
Margaret Ancona
Former EVP, Strategy and Transformation
Departed during or after this year
◇—◇———◇◇
Dale Muzzey
Chief Scientific Officer
◇—◇—◇—◇◇
Benjamin Wheeler
Chief Financial Officer
◇—◇—◇—◇◇
Paul Diaz
Former President and Chief Executive Officer
Departed during or after this year
◇—————◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Benjamin R. WheelerPSU◇—◇———◇
Benjamin R. WheelerPSU◇—◇———◇
Brian J. DonnellyPSU◇—◇———◇
Dale MuzzeyPSU◇—◇———◇
Margaret AnconaPSU◇—◇———◇
Mark VerrattiPSU◇—◇———◇
Samraat S. RahaPSU◇—◇———◇
Scott J. LefflerPSU◇—◇———◇
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Paul DiazOption◇—◇08/13/2027
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇08/13/2027
RSU◇◇——
Benjamin WheelerRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Dale MuzzeyRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Mark VerrattiRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Margaret AnconaRSU◇◇——
RSU◇◇——
Samraat RahaRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Brian DonnellyRSU◇◇——
RSU◇◇——
RSU◇◇——
Scott LefflerRSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Benjamin Wheeler
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Brian Donnelly
Chief Commercial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Dale Muzzey
Chief Scientific Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Margaret Ancona
Former EVP, Strategy and Transformation · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Mark Verratti
Chief Operating Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Paul Diaz
Former President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Samraat Raha
President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Scott Leffler
Former Chief Financial Officer · Severance agreement
Severance cash amount◇
Benefits continuation◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
S. Louise Phanstiel
Board chair
◇◇————◇
Lee N. Newcomer
◇◇————◇
Heiner Dreismann
◇◇————◇
Colleen F. Reitan
◇◇————◇
Paul M. Bisaro
◇◇————◇
Daniel M. Skovronsky
◇◇————◇
Rashmi Kumar
◇◇————◇
Mark S. Davis
◇◇————◇
Samraat S. Raha served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.
Stock ownership guideline: As of December 31, 2025, all of our directors and executive officers were in compliance with the stock ownership requirements or have additional time to meet the applicable stock ownership requirements within the five-year period to achieve compliance.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Alkermes plc ALKS
  • Bio-Techne Corporation TECH
  • BioMarin Pharmaceutical Inc. BMRN
  • Coherus BioSciences, Inc. CHRS
  • Dynavax Technologies Corporation DVAX
  • Exact Sciences Corporation EXAS
  • Exelixis Inc. EXEL
  • Guardant Health, Inc. GH
  • Incyte Corporation INCY
  • Ionis Pharmaceuticals, Inc. IONS
  • Ironwood Pharmaceuticals, Inc. IRWD
  • Natera, Inc. NTRA
  • Neogenomics, Inc. NEO
  • Neurocrine Biosciences Inc. NBIX
  • PTC Therapeutics, Inc. PTCT
  • Sarepta Therapeutics, Inc. SRPT
  • United Therapeutics Corporation UTHR
  • Vanda Pharmaceuticals Inc. VNDA
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024June 5, 2025=◇◇◇
2023June 6, 2024=◇◇◇
2022June 1, 2023=◇◇◇
2021June 2, 2022=◇◇◇
2020June 3, 2021=◇◇◇
2019December 4, 2020=◇◇◇
2018December 5, 2019=◇◇◇
2017November 29, 2018=◇◇◇
2016November 30, 2017=◇◇◇
2015December 1, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Myriad Genetics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Myriad Genetics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Myriad Genetics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Myriad Genetics' disclosed peer group is defensible, who names Myriad Genetics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
290 figures on this page: 279 cited to the filing that reported them, 11 calculated from figures it prints.
279 cited to the filing
11 calculated from the filing

Documents cited

  1. 0000899923-26-000059
    Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement Votes Votes Votes Broker For Against Abstained Non-Votes
  2. 0000899923-26-000031
    CEO Pay Ratio · Compensation Discussion and Analysis · Director Compensation · Grants of Plan-Based Awards · and 2 more sections
  3. 0000899923-25-000096
    Employment Agreement
  4. 0000899923-25-000066
    Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement Votes Votes Votes Broker For Against Abstained Non-Votes
  5. 0000899923-25-000028
    Summary Compensation Table
  6. 0000899923-24-000028
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0000899923-23-000041
  8. 0000899923-22-000085
  9. 0000899923-21-000049
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0000899923-20-000006
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001564590-19-045431
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001564590-18-030308
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001564590-17-024444
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-16-783506
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Myriad Genetics executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/MYGN (accessed 2026).
Short form: data: Velarion

The paid brief for Myriad Genetics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Myriad Genetics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Myriad Genetics discloses

The companies named in MYGN's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Alkermes plcBio-Techne CorporationBioMarin Pharmaceutical Inc.Coherus BioSciences, Inc.Dynavax Technologies CorporationExact Sciences CorporationExelixis Inc.Guardant Health, Inc.Incyte CorporationIonis Pharmaceuticals, Inc.Ironwood Pharmaceuticals, Inc.Natera, Inc.Neogenomics, Inc.Neurocrine Biosciences Inc.PTC Therapeutics, Inc.Sarepta Therapeutics, Inc.United Therapeutics CorporationVanda Pharmaceuticals Inc.Veracyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy